A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity
Obesity

About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity disease, Over weight, T2DM, interventional study, Weight loss
Eligibility Criteria
Inclusion Criteria:
- Patients with obesity disease and inadequately controlled body weight with diet and/or exercise
- BMI ≥ 25 kg/m^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35 kg/m^2 at least one obesity-related comorbidity
- Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0%
- Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female
- Visceral fat area ≥ 100 cm^2
- Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study
Exclusion Criteria:
- Pregnancy or lactating women
- Use of pharmacologically active weight-loss medications
- Bariatric surgery
- Ketoacidosis, lactic acidosis, hyperosmolar coma
- Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to screening
- Gastro-intestinal (GI) disorders associated with chronic diarrhea
- Congestive heart failure, New York Heart Association (NYHA) class III or IV
Sites / Locations
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
LIK066 2.5 mg
LIK066 10 mg
LIK066 25 mg
LIK066 50 mg
Placebo
Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.